ArticleTrials2026
Efficacy and safety of SarogLItazar as an add-on medication to Metformin and lifestyle intervention in women with PolyCystic Ovary Syndrome (SLIM-PCOS trial): study protocol for a randomized, open-label, parallel group clinical trial.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEmerging concepts on the role of insulin resistance (IR) in the pathogenesis of polycystic ovary syndrome (PCOS) have driven a shift in the therapeutic approach towards interventions targeting IR. SarogLItazar as an add-on to Metformin in PolyCystic Ovary Syndrome (SLIM-PCOS) trial aims to test the efficacy and safety of saroglitazar, a dual peroxisome proliferator-activated receptor (PPAR α/γ) agonist belonging to "glitazar" class of drugs, on top of metformin and lifestyle intervention in PCOS.
methodsSLIM-PCOS is an investigator-initiated, randomized, open label, parallel group, superiority, clinical trial. Around 140 PCOS patients will be randomized in 1:1 ratio to either of the two study groups: Group A: tablet saroglitazar (4 mg daily) + tablet metformin (500 mg twice daily) + lifestyle intervention; and Group B: tablet metformin + lifestyle intervention. Lifestyle intervention will comprise of dietary intervention and physical activity. Treatment will be given for 24 weeks and post-treatment follow up done at 36 weeks. The primary outcome is to compare the change in serum sex hormone binding globulin (SHBG) levels at 24 weeks from baseline between the two groups. Secondary efficacy outcomes include clinical (anthropometry, hirsutism, menstrual cycles); metabolic and gonadal parameters (lipid profile, IR, ovarian hormones and androgens, metabolic syndrome); hepatic steatosis on transabdominal scan and quality of life. Safety outcomes include patient reported adverse events, hematological and biochemical safety parameters. Data will be analysed as per intention to treat (ITT) principle using validated statistical software. Two-tailed P-value < 0.05 will be considered statistically significant. DISCUSSION: SLIM-PCOS trial will provide evidence on the potential therapeutic application of saroglitazar in PCOS. Based on the study outcomes and the drug's mechanism of action, future studies may be planned to investigate into the role of this novel glitazar in PCOS patients having diabetes, dyslipidemia, non-alcoholic fatty liver disease and other associated co-morbidities.
trial registrationProspectively registered with the Clinical Trials Registry of India (Trial ID: CTRI/2025/09/094653); registered September 12, 2025. https://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=142027&EncHid=25944.27666&modid=1&compid=19 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.